News

Apellis, SFJ Partnering on APL-2 Development for Treatment of CAD, wAIHA

Apellis Pharmaceuticals and SFJ Pharmaceuticals are now collaborating on the development of investigational therapy APL-2 as a treatment for cold agglutinin disease (CAD) and warm antibody hemolytic anemia (wAIHA). This follows the announcement of a newly established partnership to support the clinical program of APL-2 for the treatment…

Vienna to Host RARE2019 Meeting on Rare Diseases

About 100 scientists, researchers, pharmaceutical executives, and others will converge on Austria’s capital city early next month for the 2nd International Congress on Advanced Treatments in Rare Diseases. The March 4-5 meeting, to take place at the Hilton Am Stadtpark Vienna, features 27 speakers on a variety of disorders…

Study Urges Careful Analysis of MAIHA Patients to Optimize Treatment

The profile of patients with mixed autoimmune hemolytic anemia (MAIHA) must be carefully analyzed to facilitate diagnosis and disease management, a study says. The findings of the study, “Immunohematological and clinical characterizations of mixed autoimmune hemolytic anemia,” were published in the Asian Journal of Transfusion Science.

Apellis’ APL-2 Receives FDA’s Orphan Drug Designation for AIHA

APL-2, Apellis Pharmaceuticals‘ investigational compound for the treatment of autoimmune hemolytic anemia (AIHA) and other complement system diseases, has received the designation of orphan drug from the U.S. Food and Drug Administration (FDA) for the treatment of AIHA. “This orphan drug designation represents an important recognition by…